4512 — Wakamoto Pharmaceutical Co Share Price
0.000.00%
Last trade - 00:00- ¥8bn
- ¥4bn
- ¥9bn
- 42
- 38
- 33
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.67 | ||
| Price to Tang. Book | 0.69 | ||
| Price to Free Cashflow | 34.28 | ||
| Price to Sales | 0.98 | ||
| EV to EBITDA | 20.57 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.48% | ||
| Return on Equity | -1.51% | ||
| Operating Margin | -2.47% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 10,739.98 | 10,916.9 | 8,895.84 | 8,383.15 | 8,660.38 | n/a | n/a | -4.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -34.72 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
WAKAMOTO PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the manufacture and sale of ethical drugs such as gastrointestinal drugs and non-prescription drugs. The Company operates through four business segments. The Pharmaceuticals segment is involved in the manufacture and sale of innovator drugs, generic drugs and optiaid series supplements mainly in the ophthalmic field, as well as the commission of production and the sale of diagnostic drugs and raw materials in Japan. The Healthcare segment sales its core product Kawakami Wakamoto, the Avantbise series of medicated toothpastes that promote bad breath prevention based on evidence and Avantbise Oral Tablet mainly in the mail order business. The International segment is involved in the business related to the export of products and raw materials mainly in Asia and Europe, as well as the new license in and out business. The Real Estate Leasing segment is involved in the rental business of Coredo Muromachi.
Directors
- Nobuyuki Kamiya CHM (71)
- Yoshihiro Horio PRE (65)
- Norihisa Kojima SMD
- Hideo Sugamata SMD (65)
- Arata Igarashi MDR (54)
- Makoto Taniguchi EXO
- Noboru Yamasaki EXO
- Kimihiko Sato OTH
- Takehiko Tanigaki OTH
- Haruhisa Hirata DRC (56)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 15th, 1933
- Public Since
- May 16th, 1949
- No. of Shareholders
- 6,992
- No. of Employees
- 292
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 34,706,762
- Address
- 2-2-2, Nihombashihon-cho, CHUO-KU, 103-8330
- Web
- https://www.wakamoto-pharm.co.jp/
- Phone
- +81 332790371
- Auditors
- Gyosei Auditing
Upcoming Events for 4512
Q1 2025 Wakamoto Pharmaceutical Co Ltd Earnings Release
Similar to 4512
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Wakamoto Pharmaceutical Co share price?
As of Today at 19:23 UTC, shares in Wakamoto Pharmaceutical Co are trading at ¥226. This share price information is delayed by 15 minutes.
How has the Wakamoto Pharmaceutical Co share price performed this year?
Shares in Wakamoto Pharmaceutical Co last closed at ¥226 and the price had moved by -6.22% over the past 365 days. In terms of relative price strength the Wakamoto Pharmaceutical Co share price has underperformed the Nikkei 225 Index by -29.08% over the past year.
What are the analyst and broker recommendations for Wakamoto Pharmaceutical Co?
There is no consensus recommendation for this security.
What is the Wakamoto Pharmaceutical Co dividend yield?
The Wakamoto Pharmaceutical Co dividend yield is 1.33% based on the trailing twelve month period.
Does Wakamoto Pharmaceutical Co pay a dividend?
Last year, Wakamoto Pharmaceutical Co paid a total dividend of ¥3, and it currently has a trailing dividend yield of 1.33%.Looking ahead, the next dividend pay date is 2024-06-01.
When does Wakamoto Pharmaceutical Co next pay dividends?
We do not have data on when Wakamoto Pharmaceutical Co is to next pay dividends. The historic dividend yield on Wakamoto Pharmaceutical Co shares is currently 1.33%.
How do I buy Wakamoto Pharmaceutical Co shares?
To buy shares in Wakamoto Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Wakamoto Pharmaceutical Co?
As of the previous close price of ¥226, shares in Wakamoto Pharmaceutical Co had a market capitalisation of ¥8bn.
Where are Wakamoto Pharmaceutical Co shares listed?
Here are the trading details for Wakamoto Pharmaceutical Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4512
What kind of share is Wakamoto Pharmaceutical Co?
Based on an overall assessment of its quality, value and momentum Wakamoto Pharmaceutical Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Wakamoto Pharmaceutical Co share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Wakamoto Pharmaceutical Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Wakamoto Pharmaceutical Co. Over the past six months, its share price has underperformed the Nikkei 225 Index by -11.36%.
As of the last closing price of ¥226, shares in Wakamoto Pharmaceutical Co were trading +4.3% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Wakamoto Pharmaceutical Co PE Ratio?
The Wakamoto Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥226.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Wakamoto Pharmaceutical Co?
Wakamoto Pharmaceutical Co's management team is headed by:
- Nobuyuki Kamiya - CHM
- Yoshihiro Horio - PRE
- Norihisa Kojima - SMD
- Hideo Sugamata - SMD
- Arata Igarashi - MDR
- Makoto Taniguchi - EXO
- Noboru Yamasaki - EXO
- Kimihiko Sato - OTH
- Takehiko Tanigaki - OTH
- Haruhisa Hirata - DRC